Home > Boards > US Listed > Biotechs > Regeneron Pharmaceuticals (REGN)

After Recent Disappointments, Ocular Thera Pleases -- Market Talk

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
crudeoil24 Member Profile
Member Level 
Followed By 542
Posts 35,067
Boards Moderated 5
Alias Born 12/12/04
160x600 placeholder
Regeneron Announces the 2019 Winners of the Regeneron Prize for Creative Innovation PR Newswire (US) - 7/18/2019 7:30:00 AM
Drugmakers Rise After Trump Pricing Rule Is Blocked Dow Jones News - 7/9/2019 5:37:00 PM
Drugmakers Rise After Trump Pricing Rule Is Blocked Dow Jones News - 7/9/2019 1:58:00 PM
Regeneron to Report Second Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on August 6, 201... PR Newswire (US) - 7/8/2019 9:30:00 AM
Libtayo® (cemiplimab) Approved for Advanced Cutaneous Squamous Cell Carcinoma in the European Union PR Newswire (US) - 7/1/2019 10:00:00 AM
Committee Recommends Approval for Dermatitis Treatment Be Extended Dow Jones News - 6/28/2019 8:03:00 AM
CHMP Recommends Approval of Dupixent® (dupilumab) for Moderate-to-Severe Atopic Dermatitis in Adolescents PR Newswire (US) - 6/28/2019 6:59:00 AM
FDA Approves Sanofi, Regeneron Treatment for Chronic Rhinosinusitis with Nasal Polyposis Dow Jones News - 6/26/2019 2:30:00 PM
FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis PR Newswire (US) - 6/26/2019 1:30:00 PM
FDA Approves Dupixent® (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis PR Newswire (US) - 6/26/2019 1:29:00 PM
Regeneron, Sanofi Report Positive Topline Phase 2 Asthma Results Dow Jones News - 6/21/2019 6:39:00 AM
Regeneron and Sanofi Announce Positive Topline Phase 2 Results for IL-33 Antibody in Asthma PR Newswire (US) - 6/21/2019 12:59:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/19/2019 5:21:45 PM
Regeneron Says Early-Stage Results Positive for REGN1979 in Lymphoma Dow Jones News - 6/14/2019 7:56:00 AM
Regeneron CD20xCD3 Bispecific REGN1979 Shows Positive Results in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymp... PR Newswire (US) - 6/14/2019 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/29/2019 4:19:22 PM
Regeneron Announces Upcoming Investor Conference Presentation PR Newswire (US) - 5/23/2019 9:30:00 AM
Updated Libtayo® (cemiplimab-rwlc) Results Reinforce Durable and Substantial Response Rates in Advanced Cutaneous Squamous C... PR Newswire (US) - 5/16/2019 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/15/2019 4:05:42 PM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 5/14/2019 10:47:54 AM
FDA Approves EYLEA® (aflibercept) Injection for Diabetic Retinopathy PR Newswire (US) - 5/13/2019 4:19:00 PM
Regeneron Says FDA Approves Eylea Injection for All Diabetic Retinopathy Treatment Dow Jones News - 5/13/2019 3:29:00 PM
FDA Approves EYLEA® (aflibercept) Injection for Diabetic Retinopathy PR Newswire (US) - 5/13/2019 2:45:00 PM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 5/9/2019 4:52:51 PM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 5/7/2019 5:01:44 PM
crudeoil24 Member Level  Thursday, 10/13/16 08:41:01 AM
Re: None
Post # of 135 
After Recent Disappointments, Ocular Thera Pleases -- Market Talk
45 minutes ago - DJNF
7:49 ET - Ocular Therapeutix (OCUL) ended yesterday's trading with a $157M market cap. Regeneron (REGN) has entered a deal with the biopharma to potentially pay OCUL nearly twice that in milestone payments as part of a retinal-disease collaboration. Bigger drugmakers have made dozens of such deals with developers in recent years as to not depend just on their own pipeline but potential novel treatments created by others. In a number of cases, such agreements have ended up being the first step to a buyout. OCUL is up 23% premarket at $7.77 after having slid 8.2% this month and trading at just half of early-June levels. Then, it released more disappointing clinical data. (kevin.kingsbury@wsj.com; @kevinkingsbury)

DUKE BASKETBALL and NOTRE DAME FOOTBALL
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist